Rapid Micro Biosystems reported a 10% growth in total revenue for the second quarter of 2025, reaching $7.3 million, with recurring revenue increasing by 15%. The company also announced a new five-year, $45 million term loan facility to strengthen its financial position. Despite a net loss of $11.9 million, Rapid Micro Biosystems reaffirmed its full-year 2025 total revenue guidance of at least $32.0 million. The company’s strategic priorities remain focused on achieving long-term revenue growth, gross margin expansion, and shareholder value.

In addition to financial results, Rapid Micro Biosystems offers mission-critical automation solutions for the manufacturing and release of healthcare products, including biologics, vaccines, and sterile injectables. Their Growth Direct system automates microbial quality control testing, enhancing operational efficiency and compliance with regulations. With headquarters in Lexington, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands, Rapid Micro Biosystems is dedicated to delivering safe and consistent healthcare products.

Read more at GlobeNewswire: Rapid Micro Biosystems Reports Second Quarter 2025